RAS inhibitors by competitive inhibition of OATP1B1 or 1B3 increase CDDP-in contact with its transporter to the kidneys, and Ang II is enough effective in stimulating and increasing the activity of the OCT2, and both eventually increase kidney damage. Here, SLCO1B1 is linked to Nephropathy.